Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico City: Randomized controlled phase 1 trial of safety and immunogenicity

Pediatric Infectious Disease Journal

Volumn 30, Issue 1, 2011, Pages

  Poo, Jorge ^a   Galan, Francisco ^b   Forrat, Remi ^c   Zambrano, Betzana ^d   Lang, Jean ^c   Dayan, Gustavo H ^c  

^a Clinical Foundation (CIF BIOTEC) Medicasur Hospital   (Mexico)

^b Hospital Valle de Chalco   (Mexico)

^c SANOFI PASTEUR   (France)

^d Sanofi Pasteur   (Uruguay)

Author keywords

attenuated; children; clinical trial; dengue vaccines; phase I; vaccines

Indexed keywords

DENGUE VACCINE; LIVE ATTENUATED TETRAVALENT DENGUE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE; LIVE VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHENIA; CHILD; CLINICAL TRIAL; DENGUE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG WITHDRAWAL; EPISODIC CLUSTER HEADACHE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MEXICO; MULTICENTER STUDY; MYALGIA; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROTYPE; TREATMENT WITHDRAWAL; CONTROLLED STUDY; IMMUNOLOGY; VIREMIA; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; FEMALE; HUMANS; MALE; MEXICO; VACCINES, ATTENUATED; VIREMIA; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 78650775657     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181fe05af     Document Type: Article

References (29)

1. Gubler DJ. Dengue. In: Monath TPM, ed. Epidemiology of Arthropod-Borne Viral Disease. Boca Raton, FL: CRC Press; 1988:223-260.
2. Kautner I, Robinson MJ, Kuhnle U. Dengue virus infection: epidemiology, pathogenesis, clinical presentation, diagnosis, and prevention. J Pediatr. 1997;131:516-524.
3. Rigau-Perez JG, Clark GG, Gubler DJ, et al. Dengue and dengue haemor-rhagic fever. Lancet. 1998;352:971-977.
4. Nguyen TH, Nguyen TL, Lei HY, et al. Volume replacement in infants with dengue hemorrhagic fever/dengue shock syndrome. Am J Trop Med Hyg. 2006;74:684-691.
5. Istúriz RE, Gubler DJ, Brea del Castillo J. Dengue and dengue hemorrhagic fever in Latin America and the Caribbean. Infect Dis Clin North Am. 2000;14:121-140.
6. Guzman MG, Kouri G. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J Clin Virol. 2003;27:1-13.
7. San martin JL, Bratwhaite O, Zambrano B, et al. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg. 2010;82:128-135.
8. Pan American Health Organization. Number of reported cases of dengue & dengue hemorrhagic fever (DHF), region of the Americas (by country and subregion) 2008. Available at http://www.paho.org/English/ad/dpc/cd/ dengue-cases-2008.htm. Accessed March 3, 2010.
9. Guirakhoo F, Arroyo J, Pugachev KV, et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 2001;75:7290-7304.
10. Guirakhoo F, Weltzin R, Cambers TJ, et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000;74:5477-5485.
11. Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006;2:60-67.
12. Morrison D, Legg TJ, Billings CW, et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. 2010;201:370-377.
13. Mantel N, Aguirre M, Gulia S, et al. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods. 2008;151:40-46.
14. Porterfield JS. A plaque technique for the titration of yellow fever virus and antisera. Trans R Soc Trop Med Hyg. 1959;53:458-466.
15. Brandler S, Brown N, Ermak TH, et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg. 2005;72:74-81.
16. Russell PK, Nisalak A, Sukhavachana P, et al. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol. 1967;99:285-290.
17. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008;21:123-132.
18. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five-to twelve-year-old Thai children. Pediatr Infect Dis J. 2004;23:99-109.
19. Simasathien S, Thomas SJ, Watanaveeradej V, et al. Safety and immuno-genicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg. 2008;78:426-433.
20. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg. 2002;66:264-272.
21. Kitchener S, Nissen M, Nasveld P, et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine. 2006;24:1238-1241.
22. Dorrance WR, Frankel JW, Gordon I, et al. Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. J Immunol. 1956;77:352-364.
23. Scott RM, Eckels KH, Bancroft WH, et al. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. J Infect Dis. 1983;135:4201-4203.
24. Sun W, Cunningham D, Wasserman SS, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccin. 2009;5:33-40.
25. Edelman R, Wasserman SS, Bodison SA, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg. 2003;69:48-60.
26. Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol. 2010;338:129-143.
27. Putnak JR, de la Barrera R, Burgess T, et al. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg. 2008;79:115-122.
28. Hombach J, Solomon T, Kurane I, et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines. Geneva: WHO; September 2-3, 2004. Vaccine. 2005;23:5205-5211.
29. Guirakhoo F, Pugachev K, Zhang Z, et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004;78:4761-4775.